AbCellera Biologics (ABCL) Profit After Tax (2020 - 2023)
Historic Profit After Tax for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.
- AbCellera Biologics' Profit After Tax fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 19235.36%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
- According to the latest figures from Q4 2023, AbCellera Biologics' Profit After Tax is -$47.2 million, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Profit After Tax registered a high of $168.6 million during Q1 2022, and its lowest value of -$47.2 million during Q4 2023.
- Moreover, its 4-year median value for Profit After Tax was -$2.5 million (2020), whereas its average is $17.8 million.
- Within the past 5 years, the most significant YoY rise in AbCellera Biologics' Profit After Tax was 570062.11% (2021), while the steepest drop was 69391.01% (2021).
- AbCellera Biologics' Profit After Tax (Quarter) stood at $117.0 million in 2020, then plummeted by 48.76% to $59.9 million in 2021, then crashed by 149.86% to -$29.9 million in 2022, then tumbled by 57.73% to -$47.2 million in 2023.
- Its Profit After Tax was -$47.2 million in Q4 2023, compared to -$28.6 million in Q3 2023 and -$30.5 million in Q2 2023.